Literature DB >> 25953150

The HLA-B*4601-DRB1*0901 haplotype is positively correlated with juvenile ocular myasthenia gravis in a southern Chinese Han population.

Hui-Yu Feng1, Li-Xuan Yang, Wei-Bin Liu, Xin Huang, Li Qiu, Yan Li.   

Abstract

Myasthenia gravis (MG) is a sporadic disorder that has been increasingly linked to inherited genetic factors. Previous studies have demonstrated that human leukocyte antigen (HLA) plays an important role in the pathogenesis of MG. We determined the genotypes of the HLA-A, B, and DRB1 alleles in 257 southern Chinese Han MG patients using polymerase chain reaction sequence-based typing (PCR-SBT). The allele frequencies in the MG patients were compared to 292 healthy controls using the case-control method. HLA-A*0207, HLA-B*4601, HLA-DRB1*0403, HLA-DRB1*0901, and HLA-DRB1*1602 were more frequent in juvenile ocular MG patients than controls. HLA-DRB1*0701 was significantly reduced in the juvenile ocular MG group compared with controls. HLA-A*0207-B*4601, HLA-B*4601-DRB1*0403, HLA-B*4601-DRB1*0901, and HLA-B*4601-DRB1*1602 were found to be in strong linkage disequilibrium in juvenile ocular MG patients. Within the MG patients, there was a strong positive association between HLA-B*4601-DRB1*0901 and juvenile ocular MG patients, and the value of odds ratios (OR) decreased as the disease became more severe and the age of onset increased. We believe this could be the main heredity phenotype in juvenile ocular MG patients from southern China and may be a clinical marker to predict the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953150     DOI: 10.1007/s10072-015-2235-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

Review 1.  [Ocular myasthenia: diagnosis and treatment].

Authors:  T Stojkovic; A Béhin
Journal:  Rev Neurol (Paris)       Date:  2010-11-13       Impact factor: 2.607

2.  Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.

Authors:  E H Niks; J B M Kuks; B O Roep; G W Haasnoot; W Verduijn; B E P B Ballieux; M H De Baets; A Vincent; J J G M Verschuuren
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

3.  Association of HLA-DQA1*0101/2 and DQB1*0502 with myasthenia gravis in southern Iranian patients.

Authors:  Gholam-Ali Yousefipour; Zahra Salami; Shirin Farjadian
Journal:  Iran J Immunol       Date:  2009-06       Impact factor: 1.603

4.  Genetic factors in myasthenia gravis: a family study.

Authors:  L Kerzin-Storrar; R A Metcalfe; P A Dyer; G Kowalska; I Ferguson; R Harris
Journal:  Neurology       Date:  1988-01       Impact factor: 9.910

5.  Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis.

Authors:  Philip R Deitiker; Minako Oshima; R Glenn Smith; Dennis R Mosier; M Zouhair Atassi
Journal:  Autoimmunity       Date:  2006-06       Impact factor: 2.815

6.  The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.

Authors:  H Zach; H Cetin; E Hilger; A Paul; B Wuschitz; R Jung; E Auff; F Zimprich
Journal:  Eur J Neurol       Date:  2012-12-25       Impact factor: 6.089

7.  T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients.

Authors:  Mariapaola Marino; Maria Teresa Maiuri; Gabriele Di Sante; Flavia Scuderi; Francesca La Carpia; Nikolaos Trakas; Carlo Provenzano; Paraskevi Zisimopoulou; Francesco Ria; Socrates J Tzartos; Amelia Evoli; Emanuela Bartoccioni
Journal:  J Autoimmun       Date:  2014-01-04       Impact factor: 7.094

8.  The effect of steroid treatment and thymectomy on bone age and height development in juvenile myasthenia gravis.

Authors:  Haiyan Wang; Zhe Su; Chuanming Luo; Yan Li; Huiyu Feng; Wei Fang; Chunyan Du; Juan Deng; Fei Yu; Weibin Liu
Journal:  Neurol Sci       Date:  2013-04-26       Impact factor: 3.307

9.  Familial autoimmune myasthenia gravis with different pathogenetic antibodies.

Authors:  C Provenzano; O Arancio; A Evoli; B Rocca; E Bartoccioni; D de Grandis; P Tonali
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

Review 10.  Diagnostic and clinical classification of autoimmune myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Mélinée Frenkian-Cuvelier; Bruno Eymard
Journal:  J Autoimmun       Date:  2014-02-13       Impact factor: 7.094

View more
  5 in total

Review 1.  The immunogenetics of neurological disease.

Authors:  Maneesh K Misra; Vincent Damotte; Jill A Hollenbach
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

2.  Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset.

Authors:  T H Popperud; M K Viken; E Kerty; B A Lie
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

Review 3.  The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.

Authors:  Jeannine M Heckmann; Tarin A Europa; Aayesha J Soni; Melissa Nel
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

4.  Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3.

Authors:  Mizuki Gobaru; Kenji Ashida; Satoko Yoshinobu; Ayako Nagayama; Masaharu Kabashima; Shimpei Iwata; Nao Hasuzawa; Munehisa Tsuruta; Nobuhiko Wada; Hitomi Nakayama; Seiichi Motomura; Yuji Tajiri; Masatoshi Nomura
Journal:  Am J Case Rep       Date:  2019-11-20

5.  Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations.

Authors:  Lisa E Creary; Sridevi Gangavarapu; Stacy J Caillier; Paola Cavalcante; Rita Frangiamore; Benedicte A Lie; Mats Bengtsson; Hanne Flinstad Harbo; Susanna Brauner; Jill A Hollenbach; Jorge R Oksenberg; Pia Bernasconi; Angelina Hatlø Maniaol; Lennart Hammarström; Renato Mantegazza; Marcelo A Fernández-Viña
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.